The deadline for seeking opinions on drug price reform plan is not determined

Source: daily economic news on December 16, 2014, recently, the national development and Reform Commission issued the proposal for promoting drug price reform (Draft for comments) to eight industry associations (hereinafter referred to as the draft for comments) From the content of the document, the national drug price reform is about to start According to the draft, from January 1, 2015, the maximum retail price limit or factory price set by the original government will be cancelled This means that government priced products, which account for 23% of China's huge drug market, will be determined by the market, according to the Research Report of Guolian securities According to preliminary estimates, this will involve more than 2700 drugs Recently, Yu Mingde, President of China Pharmaceutical Enterprise Management Association, told the daily economic news that at present, the consultation on drug price reform plan has been cut off, but there is no detailed reform plan, and there is no timetable for when to issue the plan Yu Mingde said that drug price liberalization is not to let go, but to give full play to the decisive role of the market The price of medicine will be determined mainly by the market If the cost of raw materials rises, the drug price will rise; if the market competition is fierce, the drug price will fall Through market competition, drug prices will eventually find a balance between fairness and efficiency Industry insiders pointed out that with the deepening of drug price reform, the impact of drug reform on listed drug companies is different The impact on innovative pharmaceutical companies tends to be positive, while low-level generic drugs will be impacted Industry insiders pointed out that the core of the draft is to cancel the government's control over drug prices This means that the actual transaction price of drugs will be formed through market competition This time, the national development and Reform Commission released the pricing power of drugs, which will be transferred to the medical insurance center Investment bankers in the pharmaceutical industry pointed out that in general, due to the guidance of medical insurance payment standards, as well as the comprehensive restriction of the bidding procurement mechanism and medical insurance fee control mechanism, and the strengthening of market supervision, in the long run, medical insurance payment standards have a strong guiding role in market transaction prices In particular, we should establish a mechanism to save the purchase cost and return to the hospital The hospital has the power to lower the drug price In addition, after several rounds of adjustment of the medical insurance payment standard, the medical insurance payment standard can reflect the real situation of the market and keep the drug market price at a reasonable level But now it's all about frameworks There are too few detailed plans Shi lichen, senior partner of Beijing zongzong Pharmaceutical Co., Ltd., told the daily economic news that the pricing process of Chinese drugs from production to listing is that the pharmaceutical enterprises themselves report the production cost, which is subject to the approval of the development and Reform Commission It is difficult for the national development and Reform Commission to really grasp the true cost of the drug price Although the drug price ceiling has been established, the role of the market has been ignored and has not played a significant role The low-cost drugs that can cure diseases can't be bought in the market All the drugs that can be bought are high-cost drugs, which leads to higher drug prices and greater pressure on medical insurance payment According to the investment bankers, the core of the drug price reform lies in the determination of the benchmark price for medical insurance payment At present, the local pilot models are mainly Chongqing and Fujian Sanming, in which Sanming model determines the payment price of medical insurance at the lowest bidding price, and the excess part is borne by the patients; while Chongqing model establishes three payment prices: high, medium and low, but the excess part is borne by the hospital In terms of determining the payment price of medical insurance, Sanming model is relatively radical, while Chongqing model is relatively moderate The excessive part of Chongqing model is borne by the hospital, which may further curb the high price of drugs Shi lichen said that the data collection of Chongqing medical insurance settlement price mainly relies on the purchase price data and purchase volume in the platform of Chongqing drug exchange, and the establishment of medical insurance settlement price based on these data is also closer to the purchase and sale price, which is close to the actual purchase price formed by market competition The drug price reform plan should be carried out together with the bidding system and the medical insurance payment price plan, and also with the hospital reform At present, we only see the plan, and put forward the direction for other departments There are not too many detailed rules, and there is no supporting plan At the same time, he said that the benchmark price scheme of Sanming pilot in Fujian can be regarded as a medical insurance payment price The price standard is based on the lowest price of domestic generic drugs, which puts a lot of pressure on pharmaceutical enterprises This will lead to little profit for pharmaceutical enterprises Not to produce such low-cost drugs will lead to the situation that myrrh is available in the market.